Navigation Links
Baxter and The Alzheimer's Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimer's Disease
Date:8/28/2007

n Relkin and his colleagues at Weill Cornell Medical College in New York City. In this study, 24 patients with mild to moderate Alzheimer's disease were randomly assigned to receive GAMMAGARD Liquid, GAMMAGARD S/D or placebo (eight patients were treated with GAMMAGARD Liquid, eight patients were treated with GAMMAGARD S/D and eight patients received placebo) for six months. Cognitive, behavioral and functional measures were collected at baseline, three months and six months of treatment. The primary endpoints of the Phase II trial were cognitive function (as measured by ADAS-Cog score) and global function (as assessed by ADCS-CGIC rating). The pre-specified criterion for going forward with Phase III was a favorable outcome in IGIV-treated patients relative to those given placebo. Final results of the analysis of the Phase II study are expected later this year.

The Phase II study follows Dr. Relkin's earlier Phase I results in eight patients that were reported at the International Conference on Alzheimer's Disease in Madrid in July, 2006. Although these findings are promising, both studies were small and results must therefore be confirmed in a larger, sufficiently powered study.

The study protocol will be submitted to the U.S. Food and Drug Administration for review in the coming months with the intention of initiating patient recruitment early in 2008. The ADCS Phase III trial is sponsored jointly by the National Institutes of Health and Baxter. The trial will include approximately 35 leading academic centers in the U.S. that are members of ADCS.

GAMMAGARD LIQUID

[Immune Globulin Intravenous (Human)] 10%

GAMMAGARD LIQUID is indicated for the treatment of primary immunodeficiency disorders associated with defects in humoral immunity. These include but are not limited to congenital X-linked agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

Important Safety Inform
'/>"/>

SOURCE Baxter International Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Baxter Presents Phase I Inhaled Insulin Study Results at Respiratory Drug Delivery Conference
2. Baxter Announces Final Phase I/II Data and Initiation of Phase III Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine
3. Cortex Area Thinner in Youth with Alzheimers-Related Gene
4. Appendicitis: Evolving Tools to Diagnose a Classic Disease
5. Non-Invasive Diagnostic Tests for Celiac Disease
6. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
9. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
10. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
11. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Md. , May 22, 2015  RegeneRx ... today announced a peer-reviewed publication of the results ... evaluating RGN-259 (RegeneRx,s preservative-free eye drops) for the ... controlled adverse environment (CAE ® ) model.  The ... the results, which were previously disseminated by the ...
(Date:5/22/2015)... 22, 2015 According to a ... Product (Consumables, Instruments, Services), by Test Type (Indirect, Enzyme-based, ... Cytometry), by End Users - Global Forecast to 2020", ... expected to reach $736.85 Million by 2020 from $452.36 ... Browse 71 market data Tables and ...
(Date:5/22/2015)... InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), ... that its CGuard TM Embolic Prevention System reported positive ... Musialek , at the EuroPCR conference on May ... PARADIGM, an investigator-initiated P rospective evaluation of ... revascularization I n symptomatic and increased-risk asymptomatic carotid artery ...
Breaking Medicine Technology:Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 4InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4
(Date:5/24/2015)... Aliso Viejo, CA (PRWEB) May 24, 2015 ... for use in Final Cut Pro X. Utilize ProPin to ... locations in a given scene. , ProPin allows users ... are completely customizable in FCPX. With on-screen controls, video editors ... Studios allows users to pin and mark with absolute ease. , ...
(Date:5/24/2015)... May 24, 2015 ... CEO - The students were ... at the fourth annual A Day ... at Geneva National in Lake Geneva. ...     -Badger High School,         Jonathan Alfonso,         Bridget ...
(Date:5/23/2015)... 2015 On May 13, Nithyananda Yoga ... youngster's yogic power learned through meditation and initiation at ... Bangalore, India. , Yogamaatha, a nine-year-old girl from North ... profile professionals attending the 2015 Business Advocacy Summit at ... blindfolded. , In a demonstration that lasted three ...
(Date:5/23/2015)... 23, 2015 On Wednesday, May 20, ... company has been the target of a sophisticated cyberattack,” ... the company’s ongoing Information Technology (IT) security efforts in ... , The most notable attack on health insurers was ... the nation’s second largest health insurer, revealed that they ...
(Date:5/23/2015)... A live auction will be held to sell over 5,200 ... medical facilities around the United States. Various types of ... exam and much more. , The live auction will ... at 9:00am CDT each day. The equipment is at their ... IL 60160. Anyone can participate in the auction including ...
Breaking Medicine News(10 mins):Health News:Developers at Pixel Film Studios Release ProPin for Final Cut Pro X. 2Health News:Mercy Foundation Honors 16 Students for Making a Difference - Mercy Health System Javon Bea 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 4Health News:Over 5,200 Lots of Medical Equipment Will Be Sold by Live Auction 2
... The 2009-2010 INFORMS Society for Marketing Science/Marketing Science ... professors at the University of Passau and the ... Healthcare AG in their marketing investment planning for ... product portfolio in five European markets. The prize-winning ...
... ... Business , ... NY (PRWEB) June 18, 2010 -- LaVoie Group, a leader in life sciences and pharmaceutical ... Mr. Pilato will be based in New York, NY and will lead one of agency,s ...
... five lifestyle factors, international study finds , FRIDAY, June 18 ... 10 risk factors account for 90 percent of all the ... potent role. , Of that list, five risk factors usually ... diet and physical activity -- are responsible for a full ...
... Italy, Friday 18 June 2010: Systemic Lupus Erythematosus ... patients from France report that their rheumatic conditions ... according to research presented today at EULAR 2010, ... Rheumatism in Rome, Italy. Furthermore, findings of the ...
... Systemic Lupus Erythematosus (SLE) Treatment and Research Group (CSTAR) announced ... EULAR 2010, the Annual Congress of the European League Against ... has been scarce to date; but now CSTAR provides the ... date the registry has collated data from 2,104 SLE patients ...
... expression of a transporter protein called the Breast Cancer ... indicate higher disease activity and could be a barrier ... to the results of a study presented today at ... Against Rheumatism in Rome, Italy. In ...
Cached Medicine News:Health News:Prize-winning budgeting model aims for more effective marketing spending 2Health News:LaVoie Group Adds Carey Pilato As Vice President Based In New York 2Health News:Ninety Percent of Stroke Risk Due to 10 Risk Factors 2Health News:Ninety Percent of Stroke Risk Due to 10 Risk Factors 3Health News:Sex lives of patients are negatively affected by RA and SLE 2Health News:Sex lives of patients are negatively affected by RA and SLE 3Health News:Chinese systemic lupus erythematosus data reveal differences in epidemiology across continents 2Health News:Expression of certain transporter proteins may predict resistance to drug therapy 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: